Targeting ion channels in cystic fibrosis

Marcus A. Mall, Luis J V Galietta

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a characteristic defect in epithelial ion transport that plays a central role in the pathogenesis of cystic fibrosis (CF). Hence, pharmacological correction of this ion transport defect by targeting of mutant CFTR, or alternative ion channels that may compensate for CFTR dysfunction, has long been considered as an attractive approach to a causal therapy of this life-limiting disease. The recent introduction of the CFTR potentiator ivacaftor into the therapy of a subgroup of patients with specific CFTR mutations was a major milestone and enormous stimulus for seeking effective ion transport modulators for all patients with CF. In this review, we discuss recent breakthroughs and setbacks with CFTR modulators designed to rescue mutant CFTR including the common mutation F508del. Further, we examine the alternative chloride channels TMEM16A and SLC26A9, as well as the epithelial sodium channel ENaC as alternative targets in CF lung disease, which remains the major cause of morbidity and mortality in patients with CF. Finally, we will focus on the hurdles that still need to be overcome to make effective ion transport modulation therapies available for all patients with CF irrespective of their CFTR genotype.

Original languageEnglish
Article number1230
Pages (from-to)561-570
Number of pages10
JournalJournal of Cystic Fibrosis
Volume14
Issue number5
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Ion Channels
Cystic Fibrosis
Ion Transport
Mutation
Epithelial Sodium Channels
Chloride Channels
Regulator Genes
Lung Diseases
Therapeutics
Genotype
Pharmacology
Morbidity
Mortality

Keywords

  • Alternative chloride channels
  • CFTR modulators
  • ENaC
  • Pharmacotherapy
  • SLC26A9
  • TMEM16A

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Targeting ion channels in cystic fibrosis. / Mall, Marcus A.; Galietta, Luis J V.

In: Journal of Cystic Fibrosis, Vol. 14, No. 5, 1230, 01.09.2015, p. 561-570.

Research output: Contribution to journalArticle

Mall, Marcus A. ; Galietta, Luis J V. / Targeting ion channels in cystic fibrosis. In: Journal of Cystic Fibrosis. 2015 ; Vol. 14, No. 5. pp. 561-570.
@article{c5253edbd26f477a834b7b107258fc14,
title = "Targeting ion channels in cystic fibrosis",
abstract = "Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a characteristic defect in epithelial ion transport that plays a central role in the pathogenesis of cystic fibrosis (CF). Hence, pharmacological correction of this ion transport defect by targeting of mutant CFTR, or alternative ion channels that may compensate for CFTR dysfunction, has long been considered as an attractive approach to a causal therapy of this life-limiting disease. The recent introduction of the CFTR potentiator ivacaftor into the therapy of a subgroup of patients with specific CFTR mutations was a major milestone and enormous stimulus for seeking effective ion transport modulators for all patients with CF. In this review, we discuss recent breakthroughs and setbacks with CFTR modulators designed to rescue mutant CFTR including the common mutation F508del. Further, we examine the alternative chloride channels TMEM16A and SLC26A9, as well as the epithelial sodium channel ENaC as alternative targets in CF lung disease, which remains the major cause of morbidity and mortality in patients with CF. Finally, we will focus on the hurdles that still need to be overcome to make effective ion transport modulation therapies available for all patients with CF irrespective of their CFTR genotype.",
keywords = "Alternative chloride channels, CFTR modulators, ENaC, Pharmacotherapy, SLC26A9, TMEM16A",
author = "Mall, {Marcus A.} and Galietta, {Luis J V}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.jcf.2015.06.002",
language = "English",
volume = "14",
pages = "561--570",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Targeting ion channels in cystic fibrosis

AU - Mall, Marcus A.

AU - Galietta, Luis J V

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a characteristic defect in epithelial ion transport that plays a central role in the pathogenesis of cystic fibrosis (CF). Hence, pharmacological correction of this ion transport defect by targeting of mutant CFTR, or alternative ion channels that may compensate for CFTR dysfunction, has long been considered as an attractive approach to a causal therapy of this life-limiting disease. The recent introduction of the CFTR potentiator ivacaftor into the therapy of a subgroup of patients with specific CFTR mutations was a major milestone and enormous stimulus for seeking effective ion transport modulators for all patients with CF. In this review, we discuss recent breakthroughs and setbacks with CFTR modulators designed to rescue mutant CFTR including the common mutation F508del. Further, we examine the alternative chloride channels TMEM16A and SLC26A9, as well as the epithelial sodium channel ENaC as alternative targets in CF lung disease, which remains the major cause of morbidity and mortality in patients with CF. Finally, we will focus on the hurdles that still need to be overcome to make effective ion transport modulation therapies available for all patients with CF irrespective of their CFTR genotype.

AB - Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a characteristic defect in epithelial ion transport that plays a central role in the pathogenesis of cystic fibrosis (CF). Hence, pharmacological correction of this ion transport defect by targeting of mutant CFTR, or alternative ion channels that may compensate for CFTR dysfunction, has long been considered as an attractive approach to a causal therapy of this life-limiting disease. The recent introduction of the CFTR potentiator ivacaftor into the therapy of a subgroup of patients with specific CFTR mutations was a major milestone and enormous stimulus for seeking effective ion transport modulators for all patients with CF. In this review, we discuss recent breakthroughs and setbacks with CFTR modulators designed to rescue mutant CFTR including the common mutation F508del. Further, we examine the alternative chloride channels TMEM16A and SLC26A9, as well as the epithelial sodium channel ENaC as alternative targets in CF lung disease, which remains the major cause of morbidity and mortality in patients with CF. Finally, we will focus on the hurdles that still need to be overcome to make effective ion transport modulation therapies available for all patients with CF irrespective of their CFTR genotype.

KW - Alternative chloride channels

KW - CFTR modulators

KW - ENaC

KW - Pharmacotherapy

KW - SLC26A9

KW - TMEM16A

UR - http://www.scopus.com/inward/record.url?scp=84940962718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940962718&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2015.06.002

DO - 10.1016/j.jcf.2015.06.002

M3 - Article

C2 - 26115565

AN - SCOPUS:84940962718

VL - 14

SP - 561

EP - 570

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 5

M1 - 1230

ER -